Meropenem

Summary

Meropenem (CHEMBL127) is an approved small-molecule antibacterial drug (ATC J01DH02); indicated across 27 conditions including urinary tract infection and bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DH02
• Indications: 27 conditions
• Clinical trials: 130
• Chemistry: 383.5 Da · C17H25N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL127
Name	Meropenem
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	441130
ChEBI	CHEBI:43968
ATC	J01DH02
Molecular formula	C17H25N3O5S
Molecular weight	383.5
InChIKey	DMJNNHOOLUXYBV-PQTSNVLCSA-N

SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O

IUPAC name: (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

ChEBI definition: A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.

Pharmacological roles (ChEBI): antibacterial drug, antibacterial agent, drug allergen.

Also known as: ICI 194,660, ICI-194660, Meronem, Meropenem, Meropenem (as trihydrate), Meropenem anhydrous, Meropenem component of vabomere, Meropenem hydrate, Meropenem trihydrate, anhydrous, Merrem, Merrem i.v.

Parent form; salt/anhydrous children: CHEMBL4175954

Patent coverage: 8,934 distinct patent families (32,240 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Beta-lactamase OXA-48, Streptokinase A, Metallo-beta-lactamase type 2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10520	6.9	EC50	127	nM	CHEMBL_ACT_4921536
Q6XEC0	6.07	Kd	850	nM	CHEMBL_ACT_16750618

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

27 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	4	MONDO:0100338	EFO:0003103
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
meningitis	4	MONDO:0021108	MONDO:0021108
bacterial infectious disease with sepsis	4	MONDO:0005229	EFO:0003033
infectious meningitis	4	MONDO:0004796	EFO:0000584
bacterial meningitis	4	MONDO:0006670	EFO:1000831
pneumonia	3	MONDO:0005249	EFO:0003106
toxic shock syndrome	3	MONDO:0001881	EFO:0006834
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
pyelonephritis	3	MONDO:0006939	EFO:1001141
lung disorder	3	MONDO:0005275	EFO:0003818
psychiatric disorder	3	MONDO:0002025	MONDO:0002025
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049
infectious disease	2	MONDO:0005550	EFO:0005741
appendicitis	2	MONDO:0005649	EFO:0007149
tuberculosis	2	MONDO:0018076	MONDO:0018076
hematopoietic and lymphoid system neoplasm	2	MONDO:0002334	MONDO:0044881
acute pancreatitis	1	MONDO:0006515	EFO:1000652
gram-negative bacterial infections	1	MONDO:0021678	MONDO:0021678
respiratory failure	1	MONDO:0021113	EFO:0009686
osteomyelitis	0	MONDO:0005246	EFO:0003102

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 130.

Phase distribution

Phase	Trials
PHASE4	36
PHASE3	35
Not specified	20
PHASE2	16
PHASE1	10
PHASE1/PHASE2	7
PHASE2/PHASE3	5
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03671967	PHASE4	RECRUITING	PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
NCT05922124	PHASE4	RECRUITING	Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
NCT06184659	PHASE4	RECRUITING	Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
NCT06293677	PHASE4	RECRUITING	Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
NCT06342115	PHASE4	RECRUITING	Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
NCT07004049	PHASE4	RECRUITING	Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07314281	PHASE4	RECRUITING	Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
NCT07556107	PHASE4	NOT_YET_RECRUITING	The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
NCT00061438	PHASE4	COMPLETED	A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died
NCT00318552	PHASE4	COMPLETED	Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
NCT00318994	PHASE4	COMPLETED	Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
NCT00410527	PHASE4	COMPLETED	Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients
NCT01044719	PHASE4	UNKNOWN	Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT01429259	PHASE4	COMPLETED	Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
NCT01732250	PHASE4	COMPLETED	Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
NCT01992198	PHASE4	UNKNOWN	Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis
NCT02047773	PHASE4	COMPLETED	Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations
NCT02176122	PHASE4	TERMINATED	RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI’s Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
NCT02213796	PHASE4	COMPLETED	Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units
NCT02437045	PHASE4	COMPLETED	Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
NCT02463747	PHASE4	UNKNOWN	Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
NCT02506686	PHASE4	COMPLETED	Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment
NCT02615041	PHASE4	COMPLETED	The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia
NCT03452839	PHASE4	COMPLETED	Bolus Versus Continuous Infusion of Meropenem
NCT03645668	PHASE4	COMPLETED	Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients
NCT03891433	PHASE4	SUSPENDED	Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
NCT04154722	PHASE4	COMPLETED	Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
NCT04233996	PHASE4	UNKNOWN	Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients
NCT04370145	PHASE4	COMPLETED	Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
NCT04489459	PHASE4	UNKNOWN	Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
NCT04671589	PHASE4	UNKNOWN	Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
NCT05355350	PHASE4	WITHDRAWN	PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
NCT05393505	PHASE4	UNKNOWN	Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection
NCT05784844	PHASE4	WITHDRAWN	Antimicrobial Revision in Persistent Febrile Neutropenia
NCT07122596	PHASE4	COMPLETED	EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS
NCT07445282	PHASE4	COMPLETED	This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever
NCT05565222	PHASE3	RECRUITING	Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit
NCT06633718	PHASE3	NOT_YET_RECRUITING	Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
NCT07089186	PHASE3	RECRUITING	Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
NCT07326540	PHASE3	RECRUITING	Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).